Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease: A Randomized Controlled Study

• DOI: 10.1080/02713683.2024.2355659
• Publication Date: 2024-05-24T05:54:41Z
• Authors: Lingyu Dai; Zhenyu Zhong; Qiuying Wu; Yu Gao; Xiaorong Lu; Fuxiang Zhang; Chong Tang; Yao Wang; Chunjiang Zhou; Peizeng Yang
• Keywords: Vogt–Koyanagi–Harada disease

To compare the 26-week cost-effectiveness of adalimumab-corticosteroids (ADA-CS) and cyclosporine-corticosteroids (CSA-CS) for Vogt-Koyanagi-Harada (VKH).